Legacy PBMs are still failing to evolve and offer effective, patient-first healthcare—leaving employers unsatisfied. Learn more here about legacy PBMs and the future of transparency.

Self-funded health plans offer cost savings and flexibility—but only if you have the right PBM partner. Learn how employers are thriving with SmithRx’s transparent, proactive model.

Explore barriers to biosimilar adoption, such as PBM practices, regulatory limitations, and provider and patient level friction and learn what employers can do to promote uptake.

Discover how vertical integration and pricing manipulation by PBMs are limiting biosimilar access—and what employers can do to ensure savings and transparency.

Same drug, same pharmacy—very different outcomes. See how legacy PBMs inflate costs through spread and rebate retention, and how SmithRx lowers them through transparency and true alignment.

On World MS Day, move beyond awareness. Learn how early MS diagnosis, employer support, and affordable treatments make a difference

FDA grants Otulfi (Stelara biosimilar) interchangeability. SmithRx details how this win boosts patient access, lowers drug costs & drives major client savings.

ERISA compliance includes understanding the fiduciary role & the key health plan obligations. Learn more about ERISA & the connection to pharmacy benefits here.

How Encore cut PMPM pharmacy costs by 60% with SmithRx’s transparent, pass-through model and Connect 360 programs—boosting savings and member support.

Demonstrate the true ROI of your pharmacy benefits. This guide helps HR present clear financial data (PMPM, program savings, rebate transparency) that CFOs value.

Learn how biosimilars provide lower-cost alternatives to expensive biologic drugs, improving access to life-saving treatments, reducing healthcare costs, and encouraging innovation.

Hear how SmithRx rebuilt the PBM model for full transparency—no spread pricing, no rebate games, just clear costs and aligned incentives.